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A B S T R A C T   
Simultaneous determination of kynurenines, neurotransmitters, pterins and steroids linked to various neuro-
logical and metabolic diseases have important diagnostic significance for related pathology and drug monitoring. 
An improved, sensitive and selective ultra-high performance liquid chromatography coupled to electrospray 
ionization triple quadrupole mass spectrometric (UHPLC-MS/MS) method, based on our earlier publication, has 
been proposed for the quantitative measurement of 42 metabolites in human urine. The assay covers a larger 
number of analytes, uses an advanced, Waters Atlantis T3 chromatographic column and similarly meets the 
guideline of European Medicines Agency (EMA) on bioanalytical method validation. Analytical performance met 
all the EMA requirements and the assay covered the relevant clinical concentrations. Linear correlation co-
efficients were all > 0.998. Intra-day and inter-day accuracy and precision were 87− 118%, 81− 120% and 
2–20%, respectively including the lower limit of quantification (LLOQ). The assay is expected to facilitate the 
diagnosis and allows drug level monitoring from urine.   
1. Introduction 
Neurotransmitters, kynurenines and pterins play important role for 
various neurologic, metabolic and psychiatric disorders [1–3]. Concur-
rent measurement of these metabolites in human serum, cerebrospinal 
fluid (CSF) and urine helps to diagnose diverse diseases and gives op-
portunity to better understand differences in metabolic pathways. In 
addition, one can monitor complementary drug therapies on a broader 
spectrum. Not only the complementary drug levels can be measured, but 
the whole metabolic pathway, thus, the activity of metabolizing en-
zymes can also be examined (for example the determination of kynur-
enine (KYN)/triptophan (TRP) ratio suggest the indoleamine-2,3- 
dioxigenase (IDO) and triptophan-2,3-deoxigenase (TDO) activity. 
Most laboratories use disease-specific methods which contain a few (3 1 
0) metabolites [4–8] which make method development easier but limit 
the usability of the assay. 
95% of the tryptophan metabolism results in the formation of 
kynurenines. Differences in this metabolic pathway may play an 
important role in the course of diverse neurological diseases [9]. The 
remaining 5% of tryptophan is metabolized to serotonin and melatonin, 
which are essential for normal brain function [10]. The metabolic 
pathway starting from the amino acids phenylalanine and tyrosine 
(TYR) results in synthesis of several neurotransmitters that play a 
fundamental role in maintaining brain physiological function. 
A quantitative determination of some diagnostically important 
molecules in human serum and CSF has already been presented in our 
previous study [11] based on the guideline of EMA on bioanalytical 
method validation [12]. Using this methodology we now aimed to 
develop an extended method for measuring urine samples using of an 
improved chromatographic separation and wider range of analytes. 
These include metanephrine (METANEP), normetanephrine (NORME-
TANEP), tyramine (TYRA), octopamine (OCT), phenetylamine (PEA), N- 
methylphenethylamine (NMPEA), quinaldic acid (QAA), picolinic acid 
(PA), methylserotonin (Me-5HT), dihydroneopterin (NH2), tetrahy-
drobiopterin (BH4), testosterone (TESTO), creatinine (CRN) and aden-
osine 3,5-cyclic monophosphate (cAMP). The determination of 
METANEP and NORMETANEP in addition to homovanillic acid (HVA) 
and vanillylmandelic acid (VMA) is a key laboratory test for the diag-
nosis of pheochromocytoma. NORMETANEP level is significantly 
elevated in patients treated with serotonin-norepinephrine reuptake 
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inhibitors (SNRI) or tricyclic antidepressants (TCAs) [13,14]. 
The separate measurement of the individual pterin species (biopterin 
(BIO), dihydrobiopterin (BH2), BH4, neopterin (NEO) and NH2) could 
help the differential diagnosis of tetrahydrobiopterin metabolism dis-
orders (autosomal recessive guanosine triphosphate cyclohydrolase I 
(GTPCH) deficiency, 6-pyruvoyl tetrahydropterin synthase (PTPS) 
deficiency, dihydropteridine reductase (DHPR) deficiency, pterin-4- 
α-carbinolamine dehydratase (PCD) deficiency) (Fig. 1) [15,16]. 
Our aim was to develop a combined method to diagnose several 
diseases and monitor complementary drug therapies in a single run, such 
as DOPA (MADOPAR®) or BH4 (KUVAN®). 
2. Materials and methods 
2.1. Chemicals and reagents 
Unlabelled standards as well as formic acid (FA), ascorbic acid, 1,4- 
dithioerythritol (DTE), dimethyl sulfoxide (DMSO), Sigmatrix Urine 
Diluent and methanol (MeOH) were purchased from Sigma (St. Louis, 
MO, USA) and acetonitrile (ACN) from Merck (Darmstadt, Germany). 
The solvents were LC-MS grade. The deuterated internal standard (IS) 
analogues DA-d4, TYR-d4 and DOPA-d3 were purchased from 
Cambridge Isotope Laboratories (Andover, MA, USA), KA-d5, CRN-d3, 
CORT-d4, HVA-d5, NORMETANEP-d3 and METANEP-d3 from Sigma, 
QA-d3 from Buchem BV (Apeldoorn, Netherland) and 5-HT-d4 from 
Medical Isotopes Inc (Pelham, NH, USA). Steroids depleted serum was 
purchased from BBI Solutions (Crumlin, UK). Ultrapure water (18.2 MΩ 
× cm), filtered through a 0.22-μm pore size membrane, was obtained 
from a Merck Millipore Direct-Q 3 UV system (Billerica, Mass., USA). 
2.2. Instrumentation 
The UHPLC-MS/MS system and MS parameters are the same as 
previously described [11], with the exception that a Waters Atlantis T3 
(2.1 mm × 150 mm, 5 μm) column and an Atlantis T3 VanGuard Car-
tridge (Waters, Milford, MA, USA) were used for chromatographic 
analysis. 
2.3. UHPLC-MS/MS conditions 
For tuning, the analytes and IS in 0.2% FA were infused directly into 
the mass spectrometer and tuned for their molecular transitions in 
positive and/or negative ESI mode. Various percentages of acidified 
(0.2% FA) ACN/H2O and MeOH/H2O have been tested in order to check 
Fig. 1. Scheme of the 42 metabolites. TYR: tyrosine; DOPA: levodopa; 3-O-MD: 3-O-methyldopa; DA: dopamine; 3-MT: 3-methoxytyramine; DOPAC: 3,4-dihydrox-
yphenylacetic acid; HVA: homovanillic acid; VMA: vanillylmandelic acid; METANEP: metanephrine; NORMETANEP: normetanephrine; TYRA: tyramine; OCT: 
octopamine; SYN: synephrine; PEA: phenethylamine; NMPEA: N-methylphenethylamine; TRP: tryptophan; KYN: kynurenine; 3-OHK: 3-hydroxykynurenine; XA: 
xanthurenic acid; KA: kynurenic acid; QAA: quinaldic acid; AA: anthranilic acid; 3-OHAA: 3-hydroxyanthranilic acid; CIA: cinnabaric acid; QA: quinolinic acid; PA: 
picolinic acid; TPA: tryptamine; IAA: indole-3-acetic acid; 5-HTP: 5-hydroxy-tryptophan; 5-HT: serotonin; 5-HIAA: 5-hydroxyindolacetic acid; Me-5HT: methyl-
serotonin; ME: melatonin; NH2: dihydroneopterin; NEO: neopterin; BH4: tetrahydrobiopterin; BH2: dihydrobiopterin; BIO: biopterin; CORT: cortisol; TESTO: 
testosterone; CRN: creatinine; cAMP: adenosine 3,5-cyclic monophosphate. TPH: tryptophan hydroxylase; AADC: aromatic amino acid decarboxylase; MAO-A: 
Monoamine oxidase-A; INMT: indolethylamine N-methyltransferase; IDO-1: indoleamine-2,3-dioxigenase-1; IDO-2: indoleamine-2,3-dioxigenase-2; TDO: 
triptophan-2,3-deoxigenase; KMO: kynurenine 3-monooxigenase; KAT: kynurenine aminotransferase; QPRT: quinolinate phosphoribosyl transferase; PNMT: phe-
nylethanolamine N-methyltransferase; DBH: dopamine beta-hydroxylase; TH: tyrosine hydroxylase; COMT: catechol O-methyltransferase. 
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for molecule-specific ionization. 
Mobile phase A consisted of ultrapure water plus 0.2% FA (LC-MS 
grade). Mobile phase B consisted of ACN plus 0.2% FA (both LC-MS 
grade). Both eluents were prepared daily. The column temperature 
was 15 ◦C, flow rate was kept at 0.6 mL/min and the gradient profile was 
as follows: 0 – 1 min, 3% B; 1 – 5.5 min, 3% B – 7.5% B; 5.5 – 8.3 min, 
7.5% B – 16.5% B; 8.3 – 10 min, 16.5% B – 23% B; 10 – 15 min, 23% B – 
95% B; 15 – 16 min, 95% B; 16 min – 17 min 95% B – 3% B; 17 min – 20 
min 3% B. The slope of the gradient changes was linear. The injection 
volume was 15 μL and the injection technique used was ‘microliter 
pickup’. The sample compartment temperature was 10 ◦C. 
2.4. Preparation of stock solutions 
Stock solutions and IS were prepared individually, according to their 
solubility and stability. Finally, the solutions were diluted with H2O/ 
ACN/FA/ascorbic acid (96.9/3/0.2/0.02) (Diluting solution, DS) to two 
different mixtures (URINE MIX and IS MIX) according to their use 
(STable 1, STable 2). All standard stocks were stored at − 75 ◦C in 
brown Eppendorf tubes in light protected containers. 
Fig. 2. Representative chromatogram of a medium QC spiked human urine, Part 1. 1: OCT Rt = 0.99; 2: 3-OHK Rt = 2.39; 3: TYRA Rt = 2.53; 4: 3-MT Rt = 3.98; 5: 
cAMP Rt = 4.27; 6: 5-HT Rt = 4.36; 7: KYN Rt = 4.68; 8: Me-5HT Rt = 4.92; 9: PEA Rt = 5.31; 10: 3-OHAA Rt = 5.59; 11: NMPEA Rt = 6.21; 12: QAA Rt = 8.37; 13: 
TPA Rt = 8.46; 14: XA Rt = 8.94; 15: KA Rt = 9.26; 16: 5–HIAA Rt = 9.69; 17: AA Rt = 10.20; 18: ME Rt = 12.20; 19: CIA Rt = 12.50; 20: IAA Rt = 12.50; 21: TESTO 
Rt = 13.80; 22: CRN Rt = 0.94; 23: PA Rt = 1.36; 24: NEO Rt = 1.47; 25: DA Rt = 1.81; 26: QA Rt = 1.83; 27: DOPA Rt = 1.97; 28: BH2 Rt = 2.14; 29: BIO Rt = 2.32; 
30: 3-O-MD Rt = 4.47; 31: 5-HTP Rt = 5.01; 32: CORT Rt = 12.70. 
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2.5. Preparation of calibrators, quality controls (QC) and IS solutions 
The ranges of calibration standards were chosen to match the ex-
pected metabolite levels in human urine samples. The calibrators were 
prepared in a mixture of Sigmatrix Urine Diluent and 1 mg/mL DTE 
solution (1:3) and were spiked at nine concentration levels. The QCs 
were prepared as the calibrators but on different day and with different 
concentration levels as the calibrators and spiked at four levels of ana-
lytes (lower limit of quantitation (LLOQ), 3LLOQ, medium and high 
concentration). 
A mixture of ISs was prepared by appropriate dilution of the stock 
solutions in DS (IS MIX). The calibrators, QCs and IS solutions were then 
aliquoted in brown Eppendorf tubes and stored at − 75 ◦C in light pro-
tected containers until analysis. 
2.6. Collection and preparation of samples 
This study was approved by ethical committees (No. 139/2018-SZTE 
and IV/8004–1/2020/EKU). All patients participated voluntarily and 
gave their informed consent at the time of admission to the hospital for 
medical examinations, and for collecting urine samples. 
Urine samples from 10 healthy volunteers (30–48 years old) were 
obtained for the validation of the method. The patient samples were 
used for diagnosis and medication monitoring in the Metabolic and 
Newborn Screening Laboratory in Szeged. 
The urine samples were placed immediately on ice and centrifuged 
(1000 × g at 4 ◦C for 10 min) within 60 min. 90 μL 1.0 mg/mL DTE 
solution was added to 30 μL urine samples in a brown Eppendorf tube 
then stored at − 75 ◦C until analysis. 
Fig. 3. Representative chromatogram of a medium QC spiked human urine, Part 2. 33: BH4 Rt = 1.04; 34: NH2 Rt = 1.41; 35: NORME Rt = 1.46; 36: SYN Rt = 1.61; 
37: METANEP Rt = 2.00; 38: TYR Rt = 2.88; 39: TRP Rt = 8.21; 40: VMA Rt = 4.32; 41: DOPAC Rt = 8.2; 42: HVA Rt = 10.30. 
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To 120 μL of DTE diluted urine 30 μL of IS-MIX was added in a brown 
1.5 mL Eppendorf tube. After vortexing for 4 sec, 120 μL was collected in 
a 96-well round-bottom microtiter plate (Corning 3365; Sigma (St. 
Louis, MO, USA)), sealed with aluminium foil and shaken for 30 min. 
Fifteen μL was injected into the UHPLC-MS/MS system. 
2.7. Validation of the method 
For the validation of the urine analysis with UHPLC-MS/MS the 
following parameters were investigated: linearity, limit of detection 
(LOD), lower limit of quantitation (LLOQ), calibration curve, carry-over, 
intra and interday precision and accuracy, matrix effect, selectivity and 
stability. Recovery has not been calculated since the preparation of the 
samples contains only dilution steps. The validation process was eval-
uated according to the EMA guideline on bioanalytical methods [12] 
and as described in our previous study [11]. 
3. Results & discussion 
3.1. Sample management 
Prolonged light, oxygen or temperature exposure is critical for the 
stability of the measured analytes [17,18]. For this reason, the urine 
samples were transported to the laboratory on ice in light protected 
container after collection. The samples were centrifuged (3000 RPM, 
4 ◦C for 10 min). The supernatants were diluted with 1 mg/mL DTE 
solution (1:3) then aliquoted and stored at − 75 ◦C until use. 
3.2. LC-MS/MS optimization 
The UHPLC-MS/MS parameters and the preliminary experiments of 
LC and MS were the same as described previously [11]. The Waters 
Atlantis dc18 column was also tested here, but the chromatographic 
challenges set by the addition of further biomarkers and the use of urine 
specimens could only be addressed by the T3 column. MS parameters, 
polarities, retention times, related ISs and quantifiers are shown in 
STable 3. The representative chromatograms of medium QC spiked 
human urine are shown in the Supplementary material (Figs. 2–3). 
3.3. Method validation 
3.3.1. Linearity, LOD, LLOQ and calibration curve. 
Linearity, LOD and LLOQ were determined in a mixture of 1 mg/mL 
DTE, Sigmatrix Urine Diluent and IS MIX (3:1:1) then 15 μL was injected 
to the UHPLC-MS/MS system. LOD and LLOQ were calculated using the 
Analyst 1.6.2. software. The LLOQ represented the lowest concentration 
where the desired accuracy and precision were met. The determination 
coefficients were excellent (R2: 0.998 – 1.000). The calibration curves 
contained at least seven calibrator points for each analyte. The results 
are shown in STable 4. 
3.3.2. Carry-over 
Carry-over was investigated by injecting three different, high-level 
spiked human urine (prepared from 30 μL urine (0.96 mM creatinine; 
3.1 mM creatinine and 5.0 mM creatinine), 30 μL URINE MIX and 90 μL 
1.0 mg/mL DTE solution) and analyte-free DS alternately. After each 
injection, 5 needle wash cycles with DS were used to eliminate carry- 
over, which was defined as blank samples displaying peaks with a 
height > 1% of the peak of the corresponding peak. Carry-over was less 
than 0.5% for all analytes and did not exceed 15% of the value of the 
area of LLOQ. 
3.3.3. Precision and accuracy 
Intra-day accuracy and precision was determined by analysing 10 
URINE QC samples at four concentration levels in a single run (LLOQ, 
3LLOQ, medium and high spiked QCs) while interday accuracy and 
precision was determined in 5 QC samples at four concentration levels in 
three different days (STable 5). According to EMA regulation [12], ac-
curacies were acceptable when the mean concentrations were within 
15% of the nominal values (except for the LLOQ spiked samples where 
≤ 20%) and precision was satisfactory when the RSD values ≤ 15% 
(LLOQ:≤ 20%). All analytes met the requirements. 
3.3.4. Matrix effect, recovery and selectivity. 
Matrix effects were investigated in two different human urine spec-
imens (QCM_1: CRN 0.96 mM; QCM_2: CRN 3.29 mM), spiked at two 
levels (medium and high QC) and measured five times in a row. Matrix 
factor (MF) was calculated for each analyte as the ratio of the analyte/IS 
Table 1 
Creatinine normalized urine metabolite levels of 10 healthy volunteers and 5 
treated PTPS patients.  
Analyte Control (n ¼ 10) Mean ± SD 
(nmol/mmol CRN) 
PTPS patients (n ¼ 5)Mean ± 
SD (nmol/mmol CRN) 
TYR 15823 ± 13904 28655 ± 15942 
DOPA 26 ± 23 19892 ± 24346 
3-O-MD 244 ± 150 63675 ± 52304 
DA 254 ± 161 24322 ± 25277 
3-MT 89 ± 71 2588 ± 1962 
DOPAC 542 ± 369 31809 ± 16209 
HVA 4011 ± 2048 52914 ± 18246 
VMA 4006 ± 2294 1713 ± 1212 
METANEP 27 ± 18 16 ± 9 
NORMETANEP 26 ± 21 19 ± 15 
TYRA 331 ± 192 26 ± 20 
OCT <LLOQ <LLOQ 
SYN 4 ± 3 5 ± 3 
PEA 2 ± 1 1 ± 0.5 
NMPEA <LLOQ <LLOQ 
TRP 12783 ± 7648 14116 ± 4659 
KYN 747 ± 409 788 ± 539 
3-OHK 176 ± 100 256 ± 133 
XA 862 ± 511 320 ± 92 
KA 2022 ± 1099 624 ± 195 
QAA 16 ± 11 6 ± 2 
AA 13 ± 11 6 ± 3 
3-OHAA 727 ± 434 475 ± 417 
CIA <LLOQ <LLOQ 
QA 7258 ± 5270 5694 ± 2014 
PA 410 ± 300 249 ± 117 
TPA 117 ± 84 2 ± 1 
IAA 2889 ± 2331 3442 ± 962 
5-HTP 20 ± 11 46 ± 31 
5-HT 110 ± 79 50 ± 12 
5-HIAA 1090 ± 741 245 ± 95 
Me-5HT <LLOQ <LLOQ 
ME <LLOQ <LLOQ 
NH2 1055 ± 708 5201 ± 3366 
NEO 302 ± 178 928 ± 212 
BH4 1061 ± 762 220 ± 177 
BH2 525 ± 185 264 ± 243 
BIO 110 ± 54 107 ± 71 
CORT 13 ± 4 25 ± 18 
TESTO 0.8 ± 0.6 0.5 ± 0.3 
cAMP 673 ± 352 288 ± 101 
TYR: tyrosine; DOPA: levodopa; 3-O-MD: 3-O-methyldopa; DA: dopamine; 3- 
MT: 3-methoxytyramine; DOPAC: 3,4-dihydroxyphenylacetic acid; HVA: 
homovanillic acid; VMA: vanillylmandelic acid; METANEP: metanephrine; 
NORMETANEP: normetanephrine; TYRA: tyramine; OCT: octopamine; SYN: 
synephrine; PEA: phenethylamine; NMPEA: N-methylphenethylamine; TRP: 
tryptophan; KYN: kynurenine; 3-OHK: 3-hydroxykynurenine; XA: xanthurenic 
acid; KA: kynurenic acid; QAA: quinaldic acid; AA: anthranilic acid; 3-OHAA: 3- 
hydroxyanthranilic acid; CIA: cinnabaric acid; QA: quinolinic acid; PA: picolinic 
acid; TPA: tryptamine; IAA: indole-3-acetic acid; 5-HTP: 5-hydroxy-tryptophan; 
5-HT: serotonin; 5-HIAA: 5-hydroxyindolacetic acid; Me-5HT: methylserotonin; 
ME: melatonin; NH2: dihydroneopterin; NEO: neopterin; BH4: tetrahy-
drobiopterin; BH2: dihydrobiopterin; BIO: biopterin; CORT: cortisol; TESTO: 
testosterone; CRN: creatinine; cAMP: adenosine 3,5-cyclic monophosphate, 
PTPS: 6-pyruvoyltetrahydropterin synthase. 
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peak area in the presence of matrix divided by the ratio analyte/IS peak 
area in post-extraction samples without matrix, multiplied by 100%. MF 
was regarded as acceptable when the CV of MF ≤ 15%. (STable6). 
No significant endogenous matrix interferences were observed and 
there were no noticeable co-eluting compounds in the human urine 
samples. 
3.3.5. Stability 
The stability of the compounds was investigated at 3LLOQ and in the 
high QC at different storage conditions in different matrices. The com-
pounds were regarded stable when recovery and accuracy was 100 ±
20%. 
Stock solutions, urine samples were stable at least 24 h at 4 ◦C and 3 
months at − 80 ◦C. Prepared urine samples were stable in the autosam-
pler (10 ◦C) at least for 24 h. Stability tests after 3 freeze–thaw cycles 
showed no decomposition. 
3.4. Evaluation of blank matrix 
The blank matrix (Sigmatrix Urine Diluent) was injected ten times in the 
UHPLC-MS/MS system. There were no interferences with the measured 
analytes and the blank matrix except for CRN which is in the Sigmatrix Urine 
Diluent. Besides that before every measurement 1 blank matrix was injected 
into the UHPLC-MS/MS system. 
3.5. CRN measurement and CRN normalized metabolite levels 
In the routine diagnostics, urinary metabolite levels normalized to 
CRN are more appropriate than quantifying analytes in absolute units (e. 
g. ng/mL or nmol/L) in compensating differential urinary concentra-
tions [19]. The classical method for the determination of urinary 
creatinine is the Jaffe’s reaction, where creatinine produces quantita-
tively an orange colour with picric acid in alkaline medium [20]. CRN 
determined with the same UHPLC-MS/MS method as the measured 
analytes can shorten sample preparation time. 
3.6. Application of the method: Healthy human samples and substitution 
drug therapy monitoring measurements 
Of potential options to prove the clinical effectiveness of the method 
(e.g. diagnosis of BH4 deficiency [21], aromatic L-amino acid decar-
boxylase deficiency [22], neuroblastoma [23] etc.), therapy monitoring 
of 6-pyruvoyltetrahydropterin synthase deficiency (PTPS) patients was 
chosen. Substitution treatment with neurotransmitter precursors such as 
DOPA and BH4 result in marked elevation of certain analytes (3-O-MD, 
DA, DOPAC, 3-MT, HVA, BH2 and BIO) in the metabolic pathway which 
makes their analytical determination challenging. Our calibration 
ranges cover metabolite levels in health and disease for a reliable clinical 
diagnosis but analyte levels during substitution therapy can be outside 
of these ranges. Thus, urine samples of patients receiving adjunctive 
therapy was diluted 10- and 30-fold before the sample preparation. In 
PTPS due to the malfunction of the 6-pyruvoyltetrahydropterin synthase 
Fig. 4. Creatinine normalized lg values of DOPA, 3-O-MD, DA, DOPAC, 3-MT, HVA, BH4, BH2 and BIO of 5 DOPA and BH4 treated PTPS patients and 10 
non-treated healthy patients. Results are presented in an arrangement that corresponds to the biochemical routes. DOPA: levodopa; 3-O-MD: 3-O-meth-
yldopa; DA: dopamine; 3-MT: 3-methoxytyramine; DOPAC: 3,4-dihydroxyphenylacetic acid; HVA: homovanillic acid; NH2: dihydroneopterin; NEO: neopterin; BH4: 
tetrahydrobiopterin; BH2: dihydrobiopterin; BIO: biopterin; AADC: aromatic amino acid decarboxylase; COMT: catechol O-methyltransferase. 
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enzyme the production of BH4, BH2 and BIO is decreased while NEO 
and NH2 increased. BH4 is an essential cofactor of vital enzymes 
(phenylalanine hydroxylase, tyrosine hydroxylase, tryptophan hydrox-
ylase, alkylglycerol monooxygenase and nitric oxide synthase) which 
makes DOPA treatment also necessary. Table 1 contains the CRN 
normalized urinary levels in ten healthy controls and five DOPA and 
BH4 threated PTPS patients. Despite the treatment, it was shown that 
the NEO and NH2 urinary levels in the PTPS patients were still elevated 
and BH4, BH2 and BIO levels did not reach the values of the control 
group. Examination of the treatment is shown in Fig. 4, where the log-
arithmical values of metabolite concentrations are plotted for better 
comparability. 
4. Conclusion 
An improved, sensitive and selective UHPLC-MS/MS method, based 
on our earlier publication has been developed and validated for the 
quantitative measurement of TYR and TRP and their metabolites, pterins 
and steroids in human urine. The adequacy of the method has been 
proved through the guideline of EMA on bioanalytical method valida-
tion. The new method can be used to extend the quantitative study of 
metabolic pathways. Using new column and modified gradient allows to 
measure 42 analytes instead of 30. From a clinical point of view, the 
method is suitable for making a diagnosis for some metabolic and 
neurological several diseases and allows drug level monitoring from 
urine. The suitability of the method for measuring serum and CSF 
samples should be investigated in the future. 
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behalf of the International Working Group on Neurotransmitter related, Consensus 
Z. Galla et al.                                                                                                                                                                                                                                    
Journal of Chromatography B 1179 (2021) 122846
8
guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) 
deficiencies, Orphanet J Rare Dis, 15 (2020) 126, 10.1186/s13023-020-01379-8. 
[22] T. Wassenberg, M. Molero-Luis, K. Jeltsch, G.F. Hoffmann, B. Assmann, N. Blau, 
A. Garcia-Cazorla, R. Artuch, R. Pons, T.S. Pearson, V. Leuzzi, M. Mastrangelo, P. 
L. Pearl, W.T. Lee, M.A. Kurian, S. Heales, L. Flint, M. Verbeek, M. Willemsen, 
T. Opladen, Consensus guideline for the diagnosis and treatment of aromatic l- 
amino acid decarboxylase (AADC) deficiency, Orphanet J Rare Dis 12 (2017) 12, 
https://doi.org/10.1186/s13023-016-0522-z. 
[23] C.C. Swift, M.J. Eklund, J.M. Kraveka, A.L. Alazraki, Updates in Diagnosis, 
Management, and Treatment of Neuroblastoma, RadioGraphics 38 (2018) 
566–580, https://doi.org/10.1148/rg.2018170132. 
Z. Galla et al.                                                                                                                                                                                                                                    
